Xalud Therapeutics Presents Clinical Data on XT-150 in Knee Osteoarthritis at the 2023 Osteoarthritis Research Society International World Congress
March 20, 2023 08:00 ET
|
Xalud Therapeutics
• Results demonstrate that XT-150 can facilitate improved knee function during walking gait, which persists to 180 days following a single injection NEW YORK, March 20, 2023 (GLOBE NEWSWIRE) -- ...
Xalud Therapeutics CEO to Participate in Two Gene Therapy Focused Panels at BIO International Convention 2022
June 06, 2022 08:00 ET
|
Xalud Therapeutics
NEW YORK, June 06, 2022 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing novel non-viral gene therapies to treat pathologic inflammation, announced today...
Xalud Therapeutics Adds Amy Chappell, M.D., as a Strategic Advisor
April 25, 2022 08:00 ET
|
Xalud Therapeutics
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Xalud Therapeutics, a clinical-stage biotechnology company developing DNA-delivered therapeutics, today announced the appointment of Amy Chappell, M.D.,...